SCHEMBL1349277

SCHEMBL1349277

CCOC(=O)CC(C)(O)c1ccc(Cl)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.49
ABCB11 O95342 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
HTR2A P28223 1/20 0.49
PMP22 Q01453 1/20 0.49
PPARA Q07869 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.45
KMT2A Q03164 5/20 0.44
MEN1 O00255 4/20 0.44
GRIN2D O15399 1/20 0.43
GRIN3B O60391 1/20 0.43
GRIN1 Q05586 1/20 0.43
GRIN2A Q12879 1/20 0.43
GRIN2B Q13224 1/20 0.43
GRIN2C Q14957 1/20 0.43
GRIN3A Q8TCU5 1/20 0.43
MAPT P10636 1/20 0.43
MIF P14174 1/20 0.42
KDM4E B2RXH2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6822589 0.95 TSHR (0.46) TSHRABCB11CYP1A2CYP3A4HTR2A
SCHEMBL11507387 0.93 CYP1A2 (0.50) TSHRABCB11CYP1A2CYP3A4HTR2A
SCHEMBL31294747 0.87 HSD11B1 (0.41) TSHRSMN1; SMN2KMT2AMEN1MAPT
SCHEMBL1904599 0.85 GRIN2D (0.51) TSHRABCB11CYP1A2CYP3A4HTR2A
SCHEMBL11494029 0.85 KMT2A (0.47) TSHRCYP3A4KMT2AMIFALDH1A1
SCHEMBL11541910 0.84 MAPT (0.45) TSHRSMN1; SMN2KMT2AMEN1MAPT
SCHEMBL31294663 0.84 KMT2A (0.46) CYP1A2SMN1; SMN2KMT2AMEN1MAPT
SCHEMBL11506920 0.84 HSD11B1 (0.40) SMN1; SMN2MAPTGAARAB9ALMNA
SCHEMBL1349483 0.84 NPSR1 (0.47) SMN1; SMN2KMT2AMEN1MAPTKDM4E
SCHEMBL24020496 0.83 KMT2A (0.47) CYP1A2SMN1; SMN2KMT2AMEN1GRIN2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116685576-A Cysteine protease inhibitors and methods of use thereof 美商帕迪斯生物科学公司 2023-09-01 CN disclosed
US-8063234-B2 Substituted 7-sulfanylmethyl-, 7-sulfinylmethyl- and 7-sulfonylmethylindoles and the use thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-11-22 US disclosed
US-20110201564-A1 SUBSTITUTED 7-SULFANYLMETHYL, 7-SULFINYLMETHYL AND 7-SULFONYLMETHYL INDOLES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-08-18 US disclosed
US-20100105744-A1 SUBSTITUTED 7-SULFANYLMETHYL-, 7-SULFINYLMETHYL- AND 7-SULFONYLMETHYLINDOLES AND THE USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105744-A1 SUBSTITUTED 7-SULFANYLMETHYL-, 7-SULFINYLMETHYL- AND 7-SULFONYLMETHYLINDOLES AND THE USE THEREOF STS, HTR7, PCSK7 TSHR 3042/4885ABCB11 2039/4885CYP1A2 642/4885
US-20110201564-A1 SUBSTITUTED 7-SULFANYLMETHYL, 7-SULFINYLMETHYL AND 7-SULFONYLMETHYL INDOLES AND USE THEREOF HTR7, STS, INMT TSHR 1920/4885ABCB11 2833/4885CYP1A2 604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.